Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
18th November 2009 GOTHENBURG, Sweden, November 18 /PRNewswire/ -- Albireo today announced the completion of a phase 1b study showing a
favourable tolerability and safety profile of A3309 in patients with chronic...
Teva Launches TevaGrastim(R) (filgrastim)
18th November 2009 LEEDS, England, November 18 /PRNewswire/ -- Teva UK Limited has signalled its commitment to developing biosimilar
medicines by entering the G-CSF* therapy area. The launch of its proprietary
version...
Video: Crestor(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study
17th November 2009 ORLANDO, Florida, November 17 /PRNewswire/ -- JUPITER, which used CRESTOR 20 mg, is the first statin study to
demonstrate a reduction in the risk of cardiovascular (CV) events in women
without...
Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE
17th November 2009 PLEASANTON, California, November 17 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based
mechanical circulatory support therapies to save, support and restore...
New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications
17th November 2009 LEIDEN, The Netherlands, November 17 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a
consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and
Maastricht University to...
Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'
17th November 2009 SHENZHEN, China, November 17 /PRNewswire/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and
Rubella...
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
16th November 2009 ORLANDO, Florida, November 16 /PRNewswire/ -- Abbott (NYSE: ABT) today announced three-year data from the first 30
patients in the first phase of the ABSORB clinical trial, demonstrating that
its...
ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours
16th November 2009 LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase...
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
16th November 2009 INGELHEIM, Germany, November 16 /PRNewswire/ -- Data from pooled, pivotal Phase III clinical trials demonstrate that
flibanserin 100mg taken once daily at bedtime significantly increased the
number...
Medical Doctors Confirm "Divine Healing" Cases at the 6th International Christian Medical Conference
16th November 2009 KIEV, Ukraine, November 16 /PRNewswire/ -- The 6th International Christian Medical Conference was held at the
President Hotel on October 30 and 31, 2009 under the auspices of Ukraine
Organizing...
ALK Announces Landmark Asthma Prevention Trial
16th November 2009 COPENHAGEN, Denmark, November 16 /PRNewswire/ -- GAP will be the largest ever trial to investigate the asthma preventive
effect of specific immunotherapy in children (5-12 years old) with...
New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest
15th November 2009 ORLANDO, Florida, November 15 /PRNewswire/ -- The first randomized intra-arrest cooling study performed using a novel
intra-nasal cooling method showed much faster and earlier cooling in...
First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes
15th November 2009 ORLANDO, Florida, November 15 /PRNewswire/ -- Results from the RecordAF registry (REgistry on Cardiac rhythm
disORDers assessing the control of Atrial Fibrillation), presented today at
the Scientific...
Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
15th November 2009 ORLANDO, Florida, November 15 /PRNewswire/ -- Results from a new study showed patients with type 2 diabetes mellitus
who also had coronary artery disease (CAD) and received a 60 mg loading dose
and...
Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews
12th November 2009 CAMBRIDGE, Massachusetts, November 12 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company,
announced today that a review of the Company's lead compound, XMT-1001,...
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
11th November 2009 Finland, November 11 /PRNewswire/ -- An analysis conducted by the Finnish Breast Cancer Group and published
in The Lancet Oncology shows women at intermediate to high-risk of early
breast cancer...
AMT Successful in Preclinical Treatment of DMD
11th November 2009 AMSTERDAM, November 11 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that it has successfully
treated Duchenne...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
